BRD4 and MYB inhibition overcomes venetoclax resistance in EVI1-rearranged acute myeloid leukemia

Abstract EVI1-rearranged acute myeloid leukemia (AML) with inv(3)(q21q26) or t(3;3)(q21q26) represents a distinct and aggressive subtype characterized by poor prognosis and limited treatment options. However, the optimal strategy to overcome resistance to conventional therapy remains elusive. Buildi...

Descripció completa

Dades bibliogràfiques

Autors principals:	Weijia Zang, Yui Koike, Koutarou Nishimura, Atsushi Tanaka, Hiromi Yamazaki, Takaya Yamasaki, Hiromi Ito, Yifan Zhang, Yumi Aoyama, Wataru Saika, Muran Xiao, Chihiro Hasegawa, Hiroyoshi Kunimoto, Hideaki Nakajima, Fumihiko Ishikawa, Akifumi Takaori-Kondo, Daichi Inoue
Format:	Artigo
Idioma:	Inglês
Publicat:	Nature Portfolio 2025-10-01
Col·lecció:	Scientific Reports
Matèries:	Acute myeloid leukemia EVI1 Venetoclax Hypomethylating agent MYB BRD4
Accés en línia:	https://doi.org/10.1038/s41598-025-21034-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!